Flinton Capital Management LLC trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,552 shares of the medical equipment provider’s stock after selling 544 shares during the period. Flinton Capital Management LLC’s holdings in Hologic were worth $660,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Commonwealth Bank of Australia raised its holdings in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares during the period. Beck Mack & Oliver LLC acquired a new stake in shares of Hologic during the second quarter worth $209,000. Notis McConarty Edward acquired a new stake in shares of Hologic during the second quarter worth $213,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Hologic during the second quarter worth $213,000. Finally, CAPROCK Group Inc. acquired a new stake in shares of Hologic during the second quarter worth $214,000. Institutional investors and hedge funds own 96.38% of the company’s stock.

Hologic, Inc. (NASDAQ HOLX) opened at 37.47 on Monday. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80. The stock has a 50 day moving average of $37.77 and a 200-day moving average of $42.10. The company has a market cap of $10.51 billion, a P/E ratio of 13.96 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the prior year, the company posted $0.51 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. Equities research analysts expect that Hologic, Inc. will post $2.01 EPS for the current year.

WARNING: “Hologic, Inc. (HOLX) Shares Sold by Flinton Capital Management LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/09/hologic-inc-holx-shares-sold-by-flinton-capital-management-llc.html.

In other news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the completion of the sale, the director now owns 23,810 shares in the company, valued at $955,257.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,745 shares of company stock valued at $768,189. 0.79% of the stock is currently owned by corporate insiders.

A number of brokerages recently commented on HOLX. Jefferies Group LLC restated a “buy” rating and set a $49.00 price objective on shares of Hologic in a report on Wednesday, June 28th. Barclays PLC restated an “overweight” rating and set a $53.00 price objective (up from $50.00) on shares of Hologic in a report on Monday, July 17th. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Stifel Nicolaus restated a “buy” rating on shares of Hologic in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.15.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.